These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24811913)

  • 1. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
    Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
    Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
    Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
    Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
    Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
    Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
    Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
    Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
    Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
    Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
    Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
    Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
    Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
    Reiff T; Huber L; Kramer M; Delattre O; Janoueix-Lerosey I; Rohrer H
    Development; 2011 Nov; 138(21):4699-708. PubMed ID: 21989914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
    Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
    Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
    Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
    EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.